Preclinical models of pancreatic cancer (PDAC) suggest a synergistic role for combined MEK and autophagy signaling inhibition, as well as MEK and CDK4/6 pathway targeting. This evidence concerns the gene CDK4 and familial pancreatic carcinoma.